The effect of a drug Cisplatin and Thymoquinone material in the liver of rats after the induced of cancer in laboratary
Article Sidebar
Main Article Content
Abstract
Cisplatin drug is one of platinum compounds and it is in common use world wide for the treatment of a variety of human neoplasms. However in high doses it can produceundesirable toxic side effects on liver, so in this study we investigated whether Thymoqunion has protective effect on hepatotoxicity induced by cisplatin or not. Four equal-sized groups(four rats each) of adult female rats with colon cancer induced in two group unless control group by used azoxymethane carcinogen were used as (control group, AOM group cisplatin group, Thymoqunion group (TQ)). It was detected for tumor by measuring the concentration CEA in serum, it was observed significant increase (P<0.05) when injected article carcinogen totals compared with the control group. when the transaction ad these two articles focusing decreased response to treatment user. Histological examination of livers were carried out using light microscopy. Results showed that cisplatin produced histopathological changes in liver tissue, congestion and expansion of central veins, dilatation and congestion of sinusoids, with necrosis of liver cells and endothelial cells, severe fatty infiltration and necrotic foci in large areas from liver cells, congestion of sinusoids, while Thymoqunion not appear any side effect on liver tissue
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1- Sweetman, S.C. (2002). "Antineoplastic and Immune - suppressant". In: Sweetman, SC. (Ed.), Martindale: The complete Drug reference, 33rd edn., Pharmaceutical Press, London, UK. pp. 525-527. 2- Fuertes, MA; Castilla, J; Alonso, C; Pérez, JM. (2003). Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 10(3):257-66. 3- Dasari, S. and Tchounwou, P.B.(2014). Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology.740(5) : 364–378
4- Dank, M.; Zaluski, J.; BaroneM C.; Valvere, V.; Yalcin, S. (2008). Randomized phase III study comparing irinotecan combined with 5-fluorouracil chemotherapy in naïve patients with advanced Adeno carcinoma of the stomach or esophagogasric junction. Ann. Oncol., 19, 1450-1457.
5- Pal, S.; Sadhu, A.S.; Patra, S.; Mukherjea, K.K. (2008). Histological and biological assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt-ATP on the experimental animal models. J. Exp. Clin. Cancer Res., 27: 68-69.
6- Venkatesan, P.N.; Rajendran, P.; Ekambaram, G.; Sakthisekaran, D. (2008). Combination therapeutic effect of cisplatin along with Solanum trilobatum on benzo (a)pyrene induced experimental lung carcinogenesis. Nat. Prod. Res., 22, 1094-1106.
7- Hashim, F.M. and El-Kiey, M.A.(1962). Nigella sativa seeds of Egypt. J. Pharm. Sci. UAR, 1962; 3, 121-133.
8- Canonica, L., Jomoni, G., Scolastico and Bonati, A.(1963). The pharmacologically active principle in Nigella sativa. Gazz. Chem. Ital., 93, 1404-1407.
9- Badary OA, Gamal El-Din AM. (2001).Inhibitory effects of thymoquinone against 20-methylcholanthrene - induced fibrosarcoma tumorigenesis. Cancer Detect Prev. 25:362–368
10- Badary OA, Taha RA, Gamal el-Din AM, Abdel-Wahab MH.(2003). Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol. 26:87–98.
11- Sayed, M. D. Traditional medicine in health care. J. Ethnopharmacol., 1980; 2,19 – 22.
12- AbouBasha, L.I., Rashed, M.S. and Aboua-Enein,Y. TLC assay of thymoquinone in black seed oil (Nigella sativa) and identification of dithymoquinone and thymol. J. Liq. Chromatogr. 1995;18, 105-115.
13- Abduelah H.A.,Zaninal-abidin (2007).In vivo anti malarial test of Nigella sativa. different extract. American J. Pharmacol Toxico.(2):46-50.
14- Jamal A., Nasser S.,Alaa J., Luai A., Ali A. (2008). The role of Nigella sativa and number of its constituents toward azoxymethane- induced genotoxic effects and colon cancer in rats .King Faisal Specialist Hospital and Research Center.
15- Suaeyun, R.; Kinouchi, T.; Hideki, A.; Vinitketkumnven, V. and Ohnishi, Y. (1997). Inhibitory effects of lemon grass (Cymbopongon citrarus staph) on formation of Azoxymethane-induced DNA adducts and aberrant crypt foci in the rat colon. Carcinogenesis, 18: 949-955.
16- Hernando J., Von S., Grunert F.(1994).Repertoire of monoclonal antibodies reveals extensive epitope heterogeneity in cea purified from neoplasms originating from different organs. Int. J. Cancer (56): 655-661.
17- Drury, R.A.V; Wallington, E.A and Cameron, R. (1967). Carlettos histilogical techninqua 4th ed Oxford university press , New York. And Toronto .
18- Duncan,D. B. (1955). Multiple range and F-test .Biomertic;11: 42.
19-Ameet I.,Anisa S.,Suprada M.,Matthew A.(2012). Modeling Colitis - Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS). J. Vis. Exp. (67):4100.
20- Sturgeon, CM.; Lai, LC.; Duffy, MJ.(2009). Serum tumour markers: how to order and interpret them. BMJ. 22:339
21-Fawcett, D.W.; Jensh, R.P. (2002)."Bloom and Fawcett's Concise Histology". 2nd edn.,Arnold, London, pp. 208-211. 22-Gurocak ,S; Karabulut, E; Karadag, N; Ozgor, D; Ozkeles, N; Karabulut AB.(2013).Preventive effects of resveratrol against azoxymethane induced damage in rat liver. Asian Pac J Cancer Prev. 14(4):2367-70.
23- Schuppan D, Jia JD, Brinkhaus B and Hahn EG. Herbal Products for liver diseases: A therapeutic challenge for the new millennium. Hepatology Clinical Challenge (1999) 30: 1099-104.
24- Iddamaldeniya SS, Wickramasinghe N, Thabrew I, Ratnatunge N and Thammitiyagodage MG. (2003) . Protection against diethylnitrosoamine-induced hepatocarcinogenesis by an indigenous medicine comprised of Nigella sativa, Hemidesmus indicus and smilax glabra: a preliminary study. J. Carcinog. 2: 6-18 25- Shoieb, AM; Elgayyar, M; Dudrick, PS; Bell ,JL; Tithof, PK.(2003).In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol. 22(1):107-13.
26- Evan G and Littlewood T. (1998) . A matter of life and cell death. Science 281: 1317-322.
27- Attoub ,S; Sperandio, O; Raza, H; Arafat, K; Al-Salam, S; Al Sultan, MA; Al Safi, M; Takahashi, T; Adem, A.(2013).Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundam Clin Pharmacol. 27(5):557-69.
28- Gali-Muhtasib H.,Roessner A.,Schneider-Stock R.(2006).Thymoqunion :apromising anti-cancer drug from natural sources. Int. J.Biochem. Cell Biol.38(8): 1249-53.
29- Tingfang Y., Sung-Gook C., Zhengfang Y., Xiufeg P., Melissa R., Ying W.,Gautam S., Bharat B., Mingyao L.(2008). Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing
AKT and ERK signaling pathways. Mol. Cancer Ther. Jul. 7(7):1789-1796.
30- Syed, H ;Jonathan ,G.; Runhua, S.; Songlin, Z. Misty, P.; Heather K.(2010). Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res.29(1): 87
31- Katrin, S. and Lars, G.(2010). Is thymoquinone an antioxidant?. BMC Pharmacol. 10(1): A9. 32- Wei Keat, Ng; Latifah, S.; Maznah, I.(2011). Thymoquinone from Nigella sativa was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein. Toxicology in Vitro. 25( 7): 1392–1398
33- El-Sayyad, H. I.; Ismail, M. F.; Shalaby, F.M.; Abou-El-Magd, R. F.; Gaur, R. L. (2009). Histopathological effect, s of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int. J. Biol. Sci. 5, 466-473. 34-Cavalli, F., Tschopp, L., Sonntag, R. W., and Zimmermann, A. (1978). Cisplatin-induced hepatic toxicity. Cancer Treat. Rep. 62, 2125–2126. 35- Liu, J., Liu, Y., Habeebu, S. S., and Klaassen, C. D. (1998). Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 149, 24–31.
36- Rana M. A. and Ahmad H. (2012). Effect of Vitamin Con the Hepatotoxicity Induced by Cisplatin in Rats. Raf. J. Sci. 23 (2) : 23-33.
37- Kumar, V.; Cotran, R. and Robbins, S. (2003). Robbins basic pathology. 7thedition. Elsevire Science,
USA.PP.1504.